In a report published Thursday, Wedbush Securities analyst Tao Levy reiterated a Neutral rating on Boston Scientific Corporation BSX, and raised the price target from $16.00 to $17.00.
In the report, Wedbush Securities noted, "BSX reported a generally in-line quarter, led by strength from its Interventional Cardiology, CRM, and Urology/Women's Health businesses. Overall, we are encouraged that the company's new product launches are gaining traction, and we have a favorable opinion of its pipeline. However, we believe BSX's share price fairly reflects its risk/reward outlook."
Boston Scientific closed on Wednesday at $14.96.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in